August 28, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania and second in the United States in a trial assessing the safety and effectiveness of a new type of stent for blockages in the femoral artery. The new stent allows for greater flexibility within the artery and potentially less risk for stent fracture or re-narrowing after the stent is placed.
The MIMICS-2 trial is a prospective, single-arm, multicenter clinical trial of the BioMimics 3D stent system and will enroll 280 subjects in up to 40 sites in the United States and Germany. William Bachinsky, M.D., FACC, medical director of vascular services at PinnacleHealth CardioVascular Institute, serves as principal investigator locally at PinnacleHealth.
The BioMimics 3D nitinol stent has unique helical curvature that involves adapting a straight stent design to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system.
"We are very excited about having this cutting edge technology available only at PinnacleHealth for patients with claudication or pain in the legs due to leg artery blockages," said Bachinsky. "The BioMimics 3D Stent could be a game changer in femoral artery stent technology that may make the stents remain effective longer for patients."
The MIMICS-2 Study is one of more than 50 clinical trials for cardiovascular care currently underway at PinnacleHealth.
For more information: www.pinnaclehealth.org
November 14, 2025 
